A Phase 2 interventional study of pembrolizumab and lenvatinib in Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2 and Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2, sponsored by Prof. Dr. Remi A. Nout. Not yet recruiting at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Prof. Dr. Remi A. Nout · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pembrolizumab in Adenocarcinoma — 3 open to participants now, 5 under way, none of them phase 3. pembrolizumab · Adenocarcinoma.
Among the 13 studies testing pembrolizumab in Adenocarcinoma, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 12 in phase 2, and was the 13th registered.
622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.
Browse Adenocarcinoma studies →3 of the 13 studies testing pembrolizumab in Adenocarcinoma are open now, in 3 countries. Recruiting first, the newest first:
National Cancer Center Hospital East · Sites in Japan
Ages 18+
Fudan University · Sites in China
Ages 18–75
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
13 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 87 is above the median of 57 across 492 interventional studies indexed under Adenocarcinoma.
Median enrollment 26 across the 13 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Prof. Dr. Remi A. Nout as lead sponsor.
Prof. Dr. Remi A. Nout has 1 study filed under Adenocarcinoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing pembrolizumab in Adenocarcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04069273Harry H YoonNovel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | 2027-08-11 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing pembrolizumab in Adenocarcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy. It will also learn about the safety of the combination of Pembrolizumab and Lenvatinib. The main questions it aims to answer are:
Participants will:
Rationale Chemoradiation (CRT: combined external beam radiotherapy with weekly cisplatin) followed by brachytherapy has remained the standard first line treatment for locally advanced cervical (LACC) patients. Over the last decades, major improvements in radiotherapy have been pioneered through the EMBRACE studies. Most recently the outcome data of 1318 patients undergoing response adapted advanced MRI image guided intracavitary +/-interstitial brachytherapy (MR-IGABT) over and above CRT have been reported. This dose escalated approach resulted in 5-year local control of 92%, pelvic control of 87% and disease-free survival (DFS) of 68%. In this cohort, a 5-year OS of 64% was observed for stage IIIB and 67% for node positive patients. These results essentially confirm both the effectiveness of MR-IGABT for pelvic control but also the need of more effective systemic therapy approaches. Patients most at risk for recurrence and reduced 3-year DFS include patients with presence of multiple nodes in pelvic and paraaortic region or adeno/adenosquamous carcinoma histological type and those with a poor response to CRT.
Considering that both anti-angiogenesis and immune checkpoint blockade work independently in cervix cancer, a combination approach may be associated with synergy and improved outcomes. Recently, the phase III randomized placebo-controlled KEYNOTE A-18 trial investigated the combination of CRT with anti-PD-1 Pembrolizumab in patients with high-risk locally advanced cervical cancer defined as FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status. With a median follow-up of 17·9 months a 11% progression free survival (PFS) benefit at 2-years was demonstrated (68% vs 57%). Timing immunotherapy during radiotherapy and close to brachytherapy (where high dose per fraction is utilised) may allow to maximally synchronize "immunotherapy response" by taking advantage of the "inflamed" tumour microenvironment and a high radiotherapy dose fraction that is administered using brachytherapy. Lenvatinib will be initiated not earlier than 8 weeks after the last CRT and brachytherapy, to allow for sufficient healing of acute side effects of CRT.
The study hypothesizes that over and above concurrent and Pembrolizumab monotherapy, the addition of Lenvatinib administered after CRT and brachytherapy will lead to improved outcomes in this high-risk population of patients with locally advanced cervical cancer.
Objective The primary objective of the trial is to evaluate progression free survival (PFS) at 24 months (by investigator assessed RECIST 1.1) in women with high-risk locally advanced cervical cancer treated with chemoradiotherapy and Pembrolizumab followed by Pembrolizumab and Lenvatinib. Secondary Objectives include overall survival (OS), local and regional control; physician reported toxicity (CTCAE v5.0) and patient reported outcomes (EORTC QLQ-C30 and CX-24); and associated tissue, blood and imaging based translational research.
Interventions Patients will undergo standard of care chemoradiation (CRT: combined external beam radiotherapy with weekly cisplatin). Initial tumor imaging at pre-screening must have been performed within 28 days prior to the date of registration. The site study team must review pre-treatment images to confirm the participant has measurable disease per RECIST 1.1 at diagnosis. Target definition and dose reporting follow ICRU-89 and are detailed in the protocol. The elective node target volume is risk based and follows EMBRACE-II, that includes elective para-aortic radiotherapy up to the crossing of the renal vessels in patients with: ≥ 1 pathologic node at common iliac or above OR ≥ 3 pathologic nodes. With regard to organs at risk (OAR) for bowel the outer loops are contoured including the mesenteric, and for bones the whole bone from ischial tuberosity to 25mm superior of the PTV is contoured.
Use of image guided intensity modulated radiotherapy (IG-IMRT) preferably with rotational IMRT is mandatory. 3D image guidance (Cone Beam CT (CBCT) or equivalent image guidance) before each EBRT fraction is mandatory. This allows for use of reduced PTV margins (5mm from ITV45). The dose to the PTV45 should be homogenous, with at least 95% of the PTV covered by the 95% prescription isodose, and dose maximum less than 107% of the prescribed dose. Special attention is needed for the OAR irradiation in close proximity to the CTV-T HR (bladder, rectum, sigmoid and bowel). A help contour with a margin of 10 mm is generated around the CTV-T HR (CTV-T HR +10mm). The dose within this help contour should be less than 103% of 45Gy to avoid hotspots in OAR walls which are likely to also receive considerable BT dose. Lymph nodes will be boosted by simultaneous integrated boost (SIB) technique. Use of coverage probability (CoP) dose planning principles for lymph node boosting is mandatory.
Although institutional practise for nodal boosting and dose levels can be followed, the recommendation given within this protocol for the nodal boost is that total EBRT + BT dose should preferably be in the range 55-60 Gy EQD2.Total dose to PTV-Ns of about 60 Gy EQD2 can be achieved with the following fractionation schedules:
All patients should receive concurrent weekly cisplatin (40 mg/m2) during the 5 weeks of EBRT, based on standard institutional protocol. If possible, it may be advantageous to initiate EBRT and concomitant chemotherapy in the beginning of a week to avoid loss of 2 days in overall treatment time (OTT) already during the first weekend.
EBRT is followed by MRI guided adaptive brachytherapy (IGABT). The overall treatment time (OTT), defined from the first external beam fraction to the final external beam or brachytherapy fraction dose is delivered should be \< 50 days. To obtain maximal regression the treatment should always be initiated with EBRT and concomitant chemotherapy for 4-5 weeks before BT is applied in weeks. Systematic use of combined intracavitary and interstitial applicators (based on individual mould, ring, ovoids) is a preferred approach for appropriate dose adaptation which is dose escalation in particular for advanced parametrial disease and/or dose sparing in adjacent organs at risk. The first BT fraction has to be planned based on MRI with applicator in situ. Contouring for both tumour and OAR is performed for each insertion/implant of BT applicators by contouring on T2 weighted (para)-transversal MRI sequences in a dedicated 3D brachytherapy dose-planning system according to the GEC ESTRO Recommendations and the ICRU-89 report. Soft and hard dose planning constraints are detailed in the protocol. Doses are expressed as total EBRT and BT dose (each converted to EQD2). Hard constraints should be achieved in at least 90-95% of patients (per parameter), whereas soft constraints should be achieved in at least 70-80% of patients (per parameter). The priorities and balance between different DVH parameters are based on the therapeutic priorities (chance of tumor control versus risk of morbidity) as well as the level of evidence of dose effect for a given endpoint. Dose recording and reporting follows the recommendations of ICRU-89 report.
Standard of care CRT will be combined with the following study drugs:
Pembrolizumab: 5 intravenous administrations of Pembrolizumab (200 mg) every 3 weeks with the first administration at the start of chemoradiotherapy, followed by subsequent doses of 400 mg IV Pembrolizumab at 6 weeks intervals, starting week 16 up to week 102 with a maximum of 15 cycles. Pembrolizumab may be withheld after 1st year (week 54) in case of no evidence of disease. Lenvatinib: the combination with Lenvatinib will start after recovery of CRT, along with the 6 weekly cycles of Pembrolizumab, e.g. around 8-9 weeks after brachytherapy (week 16), at a dose of 20 mg daily oral and will continue up to week 48. Patients will be provided with a dosing card for Lenvatinib to complete during the treatment period. All patients will be asked to fill the dosing card once daily at the time of administrating Lenvatinib. It will include following information: dosing date, dose, dosing time, dosing missed and reason of missed dosing. They will be asked to bring the dosing card, along with their used medication packs, during their subsequent visit and will be used to assess compliance.
Haematology parameters and organ function will be checked through blood tests prior to each administration of Pembrolizumab and urine analysis prior to every other administration.
Tumor imaging is preferred to be acquired by computed tomography (CT) for uniform response evaluation. For the abdomen and pelvis, contrast-enhanced magnetic resonance imaging (MRI) may also be used when CT with iodinated contrast is contraindicated, or when local practice mandates it. MRI is the preferred modality for imaging the primary tumor when indicated. Initial tumor imaging at pre-screening (MRI and CT) must have been performed within 28 days prior to the date of registration. The site study team must review pre-treatment images to confirm the participant has measurable disease per RECIST 1.1 at diagnosis. Tumor imaging performed as part of routine clinical management is acceptable for use as screening tumor imaging if they are of diagnostic quality and performed within 28 days prior to the date of registration. Follow-up tumor imaging should be performed as per standard clinical practice. MRI is performed at 3 months and at 12 months (SOC), CT thorax/abdomen is performed at 12, 24 and 36 months. Based on clinical indications MRI may be repeated at 6 months (SOC).
Ethical considerations Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks Pembrolizumab and Lenvatinib are cancer drugs that have proven to be effective against other cancers, both alone and in combination, such as for uterine cancer. Pembrolizumab also works well in combination with chemotherapy for advanced or metastatic cervical cancer and has been shown to be beneficial during and after chemoradiation for locally advanced cervical cancer. The study hypothesizes that over and above concurrent and Pembrolizumab monotherapy, the addition of Lenvatinib administered after CRT and brachytherapy will lead to improved outcomes in this population of locally advanced cervical cancer patients that are deemed to be at high risk of recurrence based on established risk factors.
Pembrolizumab and Lenvatinib may cause side effects (detailed in the protocol). Patients may experience side effects that can sometimes be serious or life-threatening, and/or side effects that may occur after you stopping Pembrolizumab. The side effects can occur in several tissues and organs at the same time. The following side effects of Pembrolizumab are common (may affect more than 10-20 people in 100 people receiving Pembrolizumab): Itchy skin; loose or watery stools, diarrhea, cough. The following side effects with Lenvatinib are common (may affect more than 1 in 10 people): high blood pressure; bleeding; bladder irritation or discomfort (cystitis); weight loss; diarrhoea.
Apart from side effects of the study drugs, taking part in the study will cost patients extra time, requires more and potentially longer stays in the hospital, and involves some discomfort from the additional measurements that are part of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
High risk defined by either of the criteria:
Hepatitis B and C screening tests are not required unless:
Hepatitis B positive subjects:
Exclusion Criteria:
Note: Medically controlled arrhythmia would be permitted.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.
Note: no testing for Hepatitis B and Hepatitis C screening tests are not required unless:
As mandated by local health authority.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer that will undergo chemoradiation and brachytherapy
Drug: pembrolizumab and lenvatinib
Drug pages: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will undergo standard of care chemoradiation (CRT: combined external beam radiotherapy with weekly cisplatin) followed by MRI guided brachytherapy, this will be combined with the following study drugs: Pembrolizumab: 5 intravenous administrations of Pembrolizumab (200 mg) every 3 weeks with the first administration at the start of chemoradiotherapy, followed by subsequent doses of 400 mg IV Pembrolizumab at 6 weeks intervals, starting week 16 up to week 102 with a maximum of 15 cycles. Lenvatinib: the combination with Lenvatinib will start after recovery, along with the 6 weekly cycles of Pembrolizumab, e.g. around 8-9 weeks after brachytherapy (week 16), at a dose of 20 mg daily oral and will continue up to week 48.
Progression Free Survival
Actuarial Progression free survival (PFS) rate at 24 months, with a PFS event defined by either progression, using investigator assessed RECIST 1.1, or by death from any cause.
Time frame: From date of enrollment to 24 months
Overall Survival
Actuarial Overall Survival (OS) rate at 24 and at 36 months, with an OS event defined as death by any cause.
Time frame: From date of enrollment to 24 and to 36 months
Progression Free Survival
Actuarial Progression free survival (PFS) rate at 36 months, with a PFS event defined by either progression, using investigator assessed RECIST 1.1, or by death from any cause.
Time frame: From date of enrollment to 36 months
Local Control
Actuarial rate of Local Control (LC) of the primary tumor at 24 and 36 months, with an event defined as absence of tumor at the level of the cervix, detected at gynecological examination or imaging, and histological confirmed.
Time frame: From date of enrollment to 24 and to 36 months.
Regional Nodal Control
Actuarial rate of Regional Nodal Control at 24 and 36 months, with an event defined as absence of pathological pelvic and / or para-aortic lymph node involvement assessed by imaging.
Time frame: From date of enrollment to 24 and to 36 months.
Adverse Events
Adverse Events defined and graded by CTCAE v 5.0, crude and actuarial rates at 24 and 36 months.
Time frame: From date of enrollment to 24 and 36 months.
Patient reported symptoms and health related quality of life
Patient reported symptoms and health related quality of life are determined using the validated EORTC QLQC30 and Cx-24 questionnaires.
Time frame: At baseline prior to the start of treatment, at 5 weeks after start of treatment, at the first 6 weekly cycle of pembrolizumab, at 3, 6, 9, 12, 24, 36, 48 and 60 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Oct 2029, 43 months later.
Of 71 non-industry phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 94. This study's planned 43 months is below that.
Counting every sponsor, half of 93 studies reached it within 60 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pembrolizumab · Lenvatinib